Hoth Therapeutics (NASDAQ:HOTH) Announces Quarterly Earnings Results

Hoth Therapeutics (NASDAQ:HOTH) announced its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01), Zacks reports.

Hoth Therapeutics Stock Performance

HOTH traded down $0.05 on Friday, reaching $0.80. The company had a trading volume of 140,791 shares, compared to its average volume of 1,389,183. The stock has a market cap of $5.52 million, a P/E ratio of -0.59 and a beta of 0.84. Hoth Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $1.73. The company’s fifty day moving average is $0.92 and its 200 day moving average is $0.93.

Analysts Set New Price Targets

HOTH has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics in a report on Monday, November 4th. Benchmark reiterated a “speculative buy” rating and set a $3.00 target price on shares of Hoth Therapeutics in a report on Friday, October 11th. Finally, EF Hutton Acquisition Co. I upgraded Hoth Therapeutics to a “strong-buy” rating in a report on Wednesday, August 21st.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.